Valturna Combines Valsartan, Aliskiren for High Blood Pressure Treatment

 

September 18, 2009

Valturna (aliskiren and valsartan) is the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure.

It is indicated for the treatment of high blood pressure in patients not adequately controlled on aliskiren or angiotensin receptor blocker (ARB) monotherapy and as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals. Novartis Pharmaceuticals said the drug offers an important additional treatment option for physicians and hypertension patients, many of whom are not at their blood pressure goal. Valturna combines in a single pill valsartan, the active ingredient in Diovan, the number one selling branded high blood pressure medicine worldwide, and aliskiren, the active ingredient in Tekturna, the only approved direct renin inhibitor (DRI). Valturna offers significantly greater blood pressure reduction than either valsartan or aliskiren alone.

The single-pill combination Valturna targets the RAAS in two ways. The valsartan component blocks, at the receptor level, the action of angiotensin II, an important end product of the RAAS that causes blood vessels to tighten and narrow. The aliskiren component reduces angiotensin II levels by directly inhibiting renin, an enzyme produced by the kidneys that starts a process, which leads to formation of angiotensin II. An overactive RAAS is an important contributor to high blood pressure in many patients. By targeting two key points within the RAAS, Valturna helps blood vessels relax and widen so blood pressure is lowered.

The FDA approved Valturna in September 2009

For more information: www.novartis.com

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.